Adoption allows ICON to take full advantage of the Medidata "Data Experience," leveraging AI to unify data sources, standardize outputs, and reduce reconciliation efforts NEW YORK, March 20, 2025 ...

“It unifies diverse data types such as genomics, transcriptomics, imaging, and clinical tabular data to create multidimensional arrays,” he explains. “It is a powerful data model that ...

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portf ...

Icon has historically maintained a fairly conservative balance sheet. It ended 2023 with $380 million in cash and cash equivalents. The company ended the fourth quarter of 2023 with a net debt ...

Icon PLC’s $12 billion deal to acquire a rival, PRA Health Sciences, would create a contract research powerhouse and expand the role of technology in clinical trials and drug development.

On TIME Magazine’s 2024 list of World’s Best Companies ICON was ranked as the highest clinical research organisation out of 1,000 companies for the second year in a row, and in its 2025 list ...

Further, early clinical data of the ongoing global Phase 1/2 trial (NCT05438329) of BNT327 in combination with BNT325/DB-1305, a TROP2-targeting ADC candidate, including safety and early efficacy ...